MedTrace Logo

Prevention of Postoperative Events Following Reversal With Sugammadex or Neostigmine

NCT02825576 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-03-29

No results posted yet for this study

Summary

The purpose of this study is to determine if the use of sugammadex (compared with neostigmine) reduces the rate of postoperative pulmonary complications (PPCs).

Conditions

  • Pulmonary Complications

Interventions

DRUG

Sugammadex

Sugammadex 2mg/kg given for reversal agent

DRUG

Neostigmine/Glycopyrrolate

Neostigmine 50 mcg/kg plus Glycopyrrolate 10 mcg/kg given for reversal agent

Sponsors & Collaborators

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Northern Sydney and Central Coast Area Health Service

    collaborator OTHER

  • Northern Sydney Anaesthesia Research Institute

    lead OTHER

Principal Investigators

  • Ben L Olesnicky, BMBS BSc · Northern Sydney Anaesthesia Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-03
Primary Completion
2020-04-01
Completion
2021-01-01

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02825576 on ClinicalTrials.gov